RCS - BSF Enterprise PLC - Cultivated Meat Approved for Consumption in US

BSF EnterpriseAnnouncement

23/06/2023 11:30

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20230623:nRSW7591Da&default-theme=true

RNS Number : 7591D  BSF Enterprise PLC  23 June 2023

23 June 2023

 

BSF Enterprise PLC

 

("BSF" or the "Company")

 

Cultivated Meat Approved for Consumption in US

BSF (LSE: BSFA), (OTCQB: BSFAF), the Main Market listed biotech company and
owner of pioneering UK-based clinical and cellular agriculture company 3D
Bio-Tissues, is pleased to announce that cultivated meat has been approved for
sale in the USA. As the US is one of the world's biggest consumers of meat,
with approximately 40 billion kilograms consumed each year, this represents a
significant step forward for the cultivated meat industry.

Two cultivated meat companies, UPSIDE Foods, Inc. ("UPSIDE Foods") and Eat
JUST, have been granted regulatory approval from the joint USDA and FDA
framework to sell their cultivated chicken products to US consumers. UPSIDE
Foods plans to produce up to 22,000 kilograms of cultivated meat a year in the
near-term with work having started on a larger operation with annual capacity
of millions of pounds of cultivated meat products. Eat JUST intends to sell
its products through a chain of restaurants through the US with the first to
be opened shortly in Washington DC.

As one of the biggest markets in the world, with some of the most exacting
standards for food safety, this development in the USA substantially validates
cultivated meat as a viable and safe alternative to conventional meat. This
paves the way for other countries to follow suit, other companies within the
industry to receive approval, and ultimately full commercialisation of
cultivated meat.

Che Connon, CEO of 3D Bio Tissues, said:

"This announcement marks a monumental milestone in the development of the
Cultivated Meat industry. The US Government approval provides access to both
UPSIDE Foods' and Eat Just's sustainable and ethical meat products in a
country that is one of the world's biggest meat consumers.

 "US regulations for food safety are some of the most stringent in the world.
Today's approval will pave the way for the Government approval for other
producers of cultivated meat in the US, including companies that 3D Bio
Tissues is looking to partner with and provide our patented serum-free and
animal-free cell booster City-Mix(TM )to help scale up cultivated meat
production.

"This decision has the potential to rapidly accelerate the development of
the Cultivated Meat market in America and provides a clear framework for other
countries to also follow."

-Ends-

 

For further enquiries, please visit www.bsfenterprise.com
(http://www.bsfenterprise.com/)  or contact:

                                            Via SEC Newgate below

 BSF Enterprise PLC
 Che Connon - CEO & Executive Director

 Geoff Baker - Executive Director

 Shard Capital (Broker)
 Damon Heath                                0203 971 7000

 Isabella Pierre

 SEC Newgate (Financial Communications)
 Bob Huxford                                020 3757 6882

 Elisabeth Cowell                           BSF@secnewgate.co.uk

 George Esmond

 

ISIN of the Ordinary Shares is GB00BHNBDQ51

SEDOL Code is BHNBDQ5.

 

Notes to Editors

BSF Enterprise PLC (BSF) is focused on unlocking the next generation of
biotechnological solutions - using cell-based tissue engineering to help
generate cultured meat, lab-grown leather, as well as human corneas, collagen
growth and skin substitutes, as part of a radical transformation to deliver
sustainable solutions across a variety of sectors.

 

It owns 100% of 3D Bio-Tissues (3DBT), a tissue engineering with
patent-protected IP that is already producing human corneas to help restore
vision to millions of people. Building on this success, it aims to
produce the UK's first high quality lab-grown meat from its laboratory in
Newcastle the next 12 months, transforming the meat-production industry
towards an ethical and sustainable practice.

 

BSF aims to deliver growth to shareholders through the continued
commercialisation of 3DBT's IP, which has multiple applications, as well as
acquiring complementary businesses. It aims to acquire a suite of technologies
that underpins the development of tissue templating for corneas, meat and
leather, and license out the IP to manufacturers, wholesalers and distributors
to help manufacture the products at scale.

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NRAFLFFIRIIVFIV